Immunoprecise Antibodies Ltd
XTSX:IPA
Immunoprecise Antibodies Ltd
XTSX:IPA
Price:
6.5 CAD
0.78%
Market Closed
Updated:
May 6, 2024
Immunoprecise Antibodies Ltd
Cash from Financing Activities
|
Immunoprecise Antibodies Ltd
Cash from Financing Activities Peer Comparison
Comparables:
ABCL
ARCH
RP
IOT
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Immunoprecise Antibodies Ltd
XTSX:IPA
|
Cash from Financing Activities
CA$43.4m
|
CAGR 3-Years
64%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abcellera Biologics Inc
NASDAQ:ABCL
|
Cash from Financing Activities
$10.4m
|
CAGR 3-Years
-75%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Arch Biopartners Inc
XTSX:ARCH
|
Cash from Financing Activities
CA$626.7k
|
CAGR 3-Years
-38%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
15%
|
|
|
Replicel Life Sciences Inc
XTSX:RP
|
Cash from Financing Activities
CA$1.9m
|
CAGR 3-Years
24%
|
CAGR 5-Years
11%
|
CAGR 10-Years
6%
|
|
|
Innovotech Inc
XTSX:IOT
|
Cash from Financing Activities
-CA$60.2k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Immunoprecise Antibodies Ltd's Cash from Financing Activities?
Cash from Financing Activities
43.4m
CAD
43.4m
CAD
Based on the financial report for Apr 30, 2021, Immunoprecise Antibodies Ltd's Cash from Financing Activities amounts to 43.4m CAD.
What is Immunoprecise Antibodies Ltd's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 3Y
64%
64%
Over the last year, the Cash from Financing Activities growth was 25 418%. The average annual Cash from Financing Activities growth rates for Immunoprecise Antibodies Ltd have been 64% over the past three years .
You don't have any saved screeners yet
